Arkayli Biopharma

Funding and NIH signals

• NIH award NIH awarded $1M (SBIR Phase II 1R44HL184627-01, new, notice Sep 17, 2026). NIH RePORTER 1R44HL184627-01 (Sep 17, 2026)
  Evidence (1 event)

  • Sep 17, 2026 · NIH RePORTER 1R44HL184627-01
    Organization: ARKAYLI BIOPHARMA, INC.; City/State: Tracys Landing, MD; Project number: 1R44HL184627-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 999904; Administering IC: National Heart Lung and Blood Institute; Project title: Clinical Development of ARK001 Formulation as a Targeted Therapeutic for InfantileHemangioma; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals